Drug intelligence / Profile preview

CCPAB-H

Development stage: Preclinical
Lead developer: Ace Cells Lab
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

CCPAB-H is a caprine-derived (goat) polyclonal antibody candidate developed by Ace Cells Lab for the treatment and prevention of COVID-19. It is designed to target the spike protein of the SARS-CoV-2 virus, providing passive immunity by neutralizing the viral particles. The antibody is part of a broader portfolio of animal-derived polyclonal products from Ace Cells Lab, which includes bovine (BCPAB-H) and egg-derived (EGCoviPab-h) antibodies. CCPAB-H is humanized or processed to be compatible with human administration and is currently positioned as a B2B product for research and therapeutic development.

Other names: Caprine COVID-19 Polyclonal AntibodyGoat anti-SARS-CoV-2 polyclonal antibody

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on CCPAB-H.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CCPAB-H.

Explore the full profile